Sanofi is forking its own AI path, eschewing off-the-shelf tools for bespoke solutions.
Sanofi, one of the world’s largest pharmaceutical companies, has decided to build its own AI ecosystem, rather than rely on pre-packaged tools from software-as-a-service (SaaS) vendors. The move is a significant shift in the company’s approach to artificial intelligence (AI), reflecting a desire to have more control over the technology and to differentiate itself from competitors.
AI tools not living up to expectations
According to Sanofi’s Chief Digital Officer, Emmanuel Frenehard, the company was initially underwhelmed by the AI tools being offered by SaaS vendors. Instead of being wowed by AI’s potential, Frenehard was looking for more tangible results. This experience likely informed Sanofi’s decision to create its own custom tools, allowing the company to tailor AI to its specific needs.
A tailored approach
By developing its own AI ecosystem, Sanofi can design and implement tools that align with its business goals and work seamlessly with its existing systems. This approach enables the company to avoid the limitations of pre-built AI tools, which can be inflexible and one-size-fits-all. Sanofi’s custom tools will allow the company to re-imagine AI workflows, streamlining processes and automating tasks that were previously manual.
What this means
Sanofi’s decision to build its own AI ecosystem sends a strong message: the company is serious about harnessing AI to drive innovation and growth. By taking control of its AI strategy, Sanofi can respond more quickly to emerging trends and stay ahead of the competition. While the specifics of Sanofi’s custom AI tools remain under wraps, the move is a significant development in the healthcare industry’s adoption of AI technology.
